March 29, 2019 5:41pm

When you look at Q1, one thing that stands-out is the direction and divergence in the sector as the timing of “my” indication and quantamental analysis strikes a chord for portfolio appreciation

Pre-open indications: 7 Hits and 0 MISS

There is no breadline for fact based share pricing intelligence! Check your performance against my hits versus misses’ trading!

 

Duty, honor and shareholders should be a mantra – it’s mine!

My “quantamental” blend of styles; must become the “tool” for investors and traders to portfolio enrichment.

 

Markets and indexes:

  • The Dow closed up +211.22 points or +0.82% to 25,928.68
  • The S&P closed up +18.96 points or +0.67% to 2,834.40
  • The NASDAQ was up +60.15 points or +0.78% to 7,729.32

 

Henry’omics:

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

Sector equities rose on Friday as the oversold regained altitude for the second session after Wednesday’s decline with March and the quarter ending amid renewed optimism on the progress of trade talks between Washington and Beijing.

 

The question will be … is there room available for sustainable share values after four (4) up sessions this week and a new month starting?

 

Friday’s gains added to the strong performance from Q1:  he S&P 500 surged +13.1%, its biggest quarterly gain since Q3/09 also having its best Q1 since 1998. The Dow climbed +11.2% in Q1 — its best start to a year since 2013 — while the NASDAQ is on pace for its biggest quarterly gains since Q1/12, rising +16.5%.

In a review of “my” 45 covered company’s 21 sessions … there were 14 positive and 7 negative closes!

Every day, week, month and quarter I “make my bones to prepare for sector swings in 2019, investors NEED to rebalance their risk as necessary, set appropriate return expectations and ensure their portfolios are aligned with their comfort of risk.

 

Cell and gene therapy company’s worst-performers were: 

SAGE (-$0.77), SLDB (-$0.39), FIXX (-$0.23), MDXG (-$0.09) and BSTG (-$0.05)

  • Thursday’s: VSTM (-$0.24), BMRN (-$0.13), QURE (-$0.120, ADVM (-$0.10) and AGTC (-$0.07) after …
  • Wednesday’s: BLUE (-$5.26), SAGE (-$4.89), IONS (-$3.15), RGNX (-$2.27) and GBT (-$1.97).
  • Tuesday’s downside: QURE (-$2.07), RENE.L (-$2.00), BLFS (-$0.87), RGNX (-$0.39) and VCEL (-$0.35);
  • Monday’s: RENE.L (-$2.00), QURE (-$1.4), CRSP (-$1.40), BLFS (-$0.75) and BOLD (-$0.68)

 

Sector equities posting gains were:

RENE.L (+$12.00), BOLD (+$1.76), STML (+$0.56), XON (+$0.19) and ADRO (+$0.14)

  • Thursday’s: RENE.L (+$15.50), BLUE (+$5.47), ALNY (+$4.26), IONS (+$2.72) and GBT (+$1.53) after …
  • Wednesday’s: RENE.L (+$3.50), FIXX (+$0.19), CLBS (+$0.07), BCLI (+$0.07) and PSTI (+$0.017)
  • Tuesday’s: BLUE (+$6.59), SAGE (+$4.01), ALNY (+$2.97), RARE (+$2.74) and GBT (+$1.55);
  • Monday’s: SAGE (+$2.12), GBT (+$1.38), VYGR (+$1.17), RARE (+$1.08) and AXGN (+$1.01)

 

Pre-open post, “progress in alleviating the sector’s oversold conditions; however, another prime reporting issue in “our” universe is objectivity of analysis. Analyst/writers, Investors and traders are all influenced by beliefs, training and a variety of other factors from their experiences. The ability to think objectively and challenge “some” management’s execution is a crucial factor and based on accessing the evidence on its merits and a process of inference.”

 

The advance/decline line scenario of 45 covered companies:  

  • The open was positive with the A/DL to 28/13, 3 flats and 1 acquired (AST);
  • The mid-day was positive with an A/DL of 31/12 and 1 flat and 1 acquired;
  • The close was positive with an A/DL of 32/11 and 1 flat and 1 acquired;

 

Pre-open indications:  7 HIT and 0 MISS

  • bluebird bio (BLUE) closed up +$4.31 – hit;
  • Sangamo Therapeutics (SGMO) closed up +$0.22 – hit;
  • Biostage (BSTG) closed down -$0.05 – hit;
  • uniQure NV (QURE) closed up +$1.24 – hit;
  • CRISPER Therapeutics (CRSP) closed up +$0.79 – hit;
  • Editas medicine (EDIT) closed up +$0.82 – hit;
  • Intellia Therapeutics (NTLA) closed up +$0.49 – hit;

 

Tonight’s percentage (%) indicators: 

  • Range of the 32 upside was +0.12% (ONCE) to +13.26% (RENE.L) while the 11 downside ranged from -0.17% (BLFS) to -4.07% (SLDB).

Volume stat: 

  • 5 out of the 32 upside had higher (than the 3 month average) volume
  • 3 out of the 11 downside experienced greater volume (than the 3 month average)

1 flat – OSIR with 1 acquired: 1 (AST)

 

The iShares NASDAQ Biotechnology (IBB) indicator:

  • Friday was up +2.14 %;
  • Thursday was up +0.61%;
  • Wednesday was down -1.39%;
  • Tuesday was up +1.86%;
  • Monday was up +0.14%;
  • Last Friday was down -3.39%;

 

March sessions:

Friday closed POSITIVE with 11 decliners, 32 advancers, 1 flat and 1 acquired;

Thursday closed POSITIVE with 14 decliners, 30 advancers, 0 flat and 1 acquired;

Wednesday closed NEGATIVE with 35 decliners, 8 advancers, 1 flat and 1 acquired;

Tuesday closed POSITIVE with 17 decliners, 26 advancers, 2 flats and 1 acquired;

Monday (3/25) closed POSITIVE with 21 decliners, 23 advancers, 0 flats and 1 acquired;

Friday closed NEGATIVE with 40 decliners, 2 advancers, 2 flats and 1 acquired;

Thursday closed POSITIVE with 12 decliners, 31 advancers, 1 flat and 1 acquired;

Wednesday closed NEGATIVE with 25 decliners, 18 advancers, 1 flat and 1 acquired;

Tuesday closed NEGATIVE with 22 decliners, 19 advancers, 3 flats and 1 acquired;

Monday (3/18) closed POSITIVE with 17 decliners, 27 advancers and 1 acquired;

Friday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Thursday closed NEGATIVE with 30 decliners, 13 advancers and 2 flats;

Wednesday closed POSITIVE with 12 decliners, 30 advancers and 3 flats;

Tuesday closed POSITIVE with 13 decliners, 30 advancers and 2 flats;

Monday (3/11) closed POSITIVE with 7 decliners, 37 advancers and 1 flat;

Friday closed POSITIVE with 20 decliners, 22 advancers and 3 flats;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flats;

Wednesday closed NEGATIVE with 39 decliners, 5 advancers and 1 flat;

Tuesday (3/4) closed POSITIVE with 17 decliners, 23 advancers and 5 flats;

Monday (3/1) closed NEGATIVE with 24 decliners, 18 advancers and 3 flats;

Friday (3/1) closed POSITIVE with 11 decliners, 32 advancers and 2 flats;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.